Small molecule · Inhibitor · developed by Ocular Therapeutix
OTX-TKI is an intravitreal axitinib implant, axitinib being a tyrosine kinase inhibitor. It is being studied in neovascular age-related macular degeneration.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06495918 | Phase 3 | Neovascular Age-related Macular Degeneration | Active not recruiting | OCUL |
| NCT06223958 | Phase 3 | Neovascular Age-Related Macular Degeneration | Active not recruiting | OCUL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neovascular Age-Related Macular Degeneration
Updated Oct 25, 2026. Something wrong or missing? Report it on the OCUL page.
See OCUL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OCUL catalysts and pipeline →